Who are Liserdol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Abilify, Risperdal, Abilify, Risperdal, Delysid, Ergot.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metergoline.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Liserdol — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liserdol (METERGOLINE) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: metergoline. Area: Other.

phase 2 metergoline 5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6 Other Small molecule Live · refreshed every 30 min

Target snapshot

Liserdol (METERGOLINE). Liserdol works by binding to serotonin receptors in the brain, specifically the 5-hydroxytryptamine receptor 2C.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Liserdol TARGET	METERGOLINE		phase 2	metergoline	5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6
Abilify	aripiprazole	Generic (originally Otsuka/BMS)	marketed	Third-generation antipsychotic (D2 partial agonist)	5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6	2002-11-15
Risperdal	risperidone	Johnson & Johnson (Janssen)	marketed	Atypical Antipsychotic [EPC]	5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6	1993-12-29
Abilify	Abilify	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	marketed		5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6
Risperdal	Risperdal	Ohio State University	marketed		5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6
Delysid	LYSERGIDE		marketed	lysergide	5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6
Ergot	Ergot	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	marketed		5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-06-26 — Risperdal · 10406160 · Formulation · US
2026-07-28 — Abilify · 9125939 · Method of Use · US
2026-09-14 — Abilify · 7978064 · Formulation · US
2026-09-26 — Risperdal · 9597402 · Formulation · US
2026-09-26 — Risperdal · 10058554 · Method of Use · US
2026-11-05 — Risperdal · 11110093 · Formulation · US
2027-03-02 — Abilify · 8759350 · Method of Use · US
2027-11-12 — Risperdal · 8741327 · Formulation · US
2027-11-12 — Risperdal · 8221778 · Formulation · US
2027-11-19 — Abilify · 9444503 · Formulation · US
2028-02-13 — Risperdal · 11712475 · Method of Use · US
2028-02-13 — Risperdal · 10010612 · Formulation · US
2028-02-13 — Risperdal · 9180197 · Formulation · US
2028-02-13 — Risperdal · 11013809 · Formulation · US
2028-02-13 — Risperdal · 10376590 · Method of Use · US
2028-02-13 — Risperdal · 9186413 · Method of Use · US
2028-12-16 — Abilify · 9119554 · Formulation · US
2029-03-05 — Abilify · 9258035 · Formulation · US
2029-03-05 — Abilify · 9060708 · Formulation · US
2029-04-09 — Abilify · 8674825 · Formulation · US
2029-07-06 — Abilify · 8956288 · Formulation · US
2029-07-26 — Abilify · 10441194 · Formulation · US
2029-08-19 — Abilify · 8945005 · Formulation · US
2029-09-15 — Abilify · 9433371 · Formulation · US
2029-12-05 — Abilify · 8718193 · Formulation · US
2029-12-15 — Abilify · 9149577 · Formulation · US
2030-03-29 — Abilify · 8847766 · Formulation · US
2030-04-27 — Abilify · 8545402 · Formulation · US
2030-06-21 — Abilify · 8114021 · Formulation · US
2030-09-15 — Abilify · 11464423 · Formulation · US

Sponsor landscape (metergoline class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Liserdol — Competitive Intelligence Brief. https://druglandscape.com/ci/metergoline. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing